One important change is that they state, GLP-1 RA therapy may be continued preoperatively in patients without elevated risk of delayed gastric emptying. The risk factors they state include: escalation phase of dosing, higher dose, weekly dosing (as opposed to daily dosing), gastrointestinal symptoms (nausea, vomiting, abdominal pain, dyspepsia, constipation), and medical conditions that may cause delayed gastric emptying
People with reduced NOS3 activity may experience more pronounced vascular effects from BPC-157 at the same dose including blood pressure changes, flushing, or headaches
Yet, the effect of homocysteine lowering on cardiovascular disease risk reduction is debated
Chemical Reviews 109 , 190212, (2009)
32.1A )